HK Stock Concept Tracker | ESMO Annual Congress: Chinese Pharmaceutical Companies Successively Announce Latest Innovative Drug Data (with Concept Stocks)

Title context: HK Stock Concept Tracker | ESMO Annual Congress: Chinese Pharmaceutical Companies Successively Announce Latest Innovative Drug Data (with Concept Stocks) The 2026 European Society for Medical Oncology (ESMO) Annual Congress was held from October 23 to 27. At the 2026 ESMO Congress, Eli Lilly presented the first clinical data for its investigational next-generation FR-targeted ADC in platinum-sensitive ovarian cancer. According to Guolian Minsheng Securities research, a total of 96 late-breaking abstracts were published at this year's ESMO Annual Congress, of which 31 were drug-related studies from Chinese companies. Multiple core data readouts are expected to become near-term stock price catalysts for the relevant listed companies. In addition, AI drug discovery catalysts have been recently, with the industry focus gradually shifting from model capabilities to wet-lab validation efficiency and other aspects. Among them, the personalized cancer vaccine intismeran autogene jointly developed by two pharmaceutical giants, Merck & Co. and Moderna, will also read out Phase 3 confirmatory data at the ESMO Annual Congress, validating the effectiveness of AI assistance and becoming a major focus of market attention. China Securities Co.,Ltd. stated that the overall AI drug discovery market remains relatively small at present, but with increasing capital participation, technological iteration, and the gradual market entry and validation of AI drug discovery pipelines, the industry is expected to gradually enter a harvest period. Huatai released a research report stating that progress in the ADC track has been frequent recently. At the ESMO Annual Congress, multiple ADC drugs demonstrated good efficacy, further validating their potential as cornerstone drugs for next-generation tumor treatment. Licensing transactions related to ADCs continue to land, with transaction amounts continuing to rise. As of the early morning of October 26, pharmaceutical companies that had already published data at the ESMO Annual Congress mainly include: AKESO (09926): Results of the HARMONi-GI1 study of ivonescimab combined with chemotherapy versus durvalumab combined with chemotherapy for first-line treatment of advanced biliary tract cancer were highlighted at 2026 ESMO; SKB BIO (06990): Announced that the company has presented multiple clinical research results at the 2026 European Society for Medical Oncology (ESMO) Congress held in Madrid, Spain, from October 23 to 27, covering data related to the trophoblast cell-surface antigen 2 (TROP2)-targeted antibody-drug conjugate (ADC) sac-TMT () and the B7-H3-targeted ADC SKB500; HUTCHMED (00013): Presented data from the global Phase III SAFFRON study at the 2026 European Society for Medical Oncology (ESMO) Annual Congress, simultaneously published in the New England Journal of Medicine ASCENTAGE-B (06855): APG-1252 combined with osimertinib showed preliminary good tolerability in NSCLC patients harboring EGFR mutations; JACOBIO-B (01167.HK) announced that the company presented clinical data on the combination therapy of its self-developed glecirasib (KRAS G12C inhibitor) and JAB-3312 (SHP2 inhibitor) in an oral presentation at the 2023 European Society for Medical Oncology Congress (ESMO2023); CSTONE PHARMA-B (02616): Announced that the Phase III GEMSTONE-303 study of sugemalimab () combined with chemotherapy for first-line treatment of locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma has been selected as a late-breaking abstract (LBA) at the 2023 European Society for Medical Oncology (ESMO) Annual Congress, with detailed data presented in an oral presentation. CStone Pharmaceuticals (02616.HK) announced GEMSTONE-303 study results: combined with chemotherapy significantly improved PFS and OS; ABBISKO-B (02256): Abbisko Therapeutics presented the latest clinical progress of irpagratinib and pimicotinib at the ESMO Annual Congress; EDDING GENOR (06998): Announced that preliminary data from the first-in-human Phase I clinical study of GB268 were published in poster form at the 2026 European Society for Medical Oncology (ESMO) Annual Congress (Abstract No.: 1963P). The study evaluated the safety and tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of GB268 monotherapy in patients with previously treated advanced solid tumors. LEADS BIOLABS-B (09887): Announced that on October 24, 2026, updated results from the first-in-human clinical study of LBL-034 (GPRC5D/CD3 bispecific T-cell engager, TCE) for the treatment of relapsed/refractory multiple myeloma (RRMM) were presented in an oral presentation at the 2026 European Society for Medical Oncology Annual Congress (2026 ESMO). GENFLEET-B (02595): Announced that preliminary research data of GFH276 (oral molecular glue pan-RAS inhibitor) for the treatment of previously treated RAS-mutant solid tumors were featured as a late-breaking abstract and on-site oral presentation at the ESMO (European Society for Medical Oncology) Annual Congress on October 25 local time. GFH276 has shown encouraging preliminary efficacy and good safety in the dose-escalation phase; CARSGEN-B (02171): research results presented at the 2026 ESMO Annual Congress; IMPACT THERAP-B (07630): Presented the latest clinical data of senaparib with selective PARP1 inhibitors IMP1734 and IMP1707 in poster form at the 2026 European Society for Medical Oncology Congress; SBP GROUP (01177): TQB2102 "HER2 bispecific epitope ADC" presented two clinical data sets at 2026 ESMO. ............. CITIC SEC outlook for the second half of the year and beyond: WCLC, ESMO, ACR, ASH and other conferences will be held successively, multiple registrational studies are entering readout windows, global Phase III/registrational studies continue to advance, and overseas commercialization is gradually being realized, all of which are expected to jointly drive the performance of the innovative drug sector.